Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Certolizumab pegol for hidradenitis suppurativa: Case report and literature review

    Research output: Contribution to journalLetterResearchpeer-review

  2. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature

    Research output: Contribution to journalReviewResearchpeer-review

  4. Treatment of adult atopic dermatitis patients according to disease characteristics and demographics

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reduction in actinic keratoses following 9-valent human papilloma virus vaccination

    Research output: Contribution to journalLetterResearchpeer-review

  1. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of the spirometric definition on comorbidities in chronic obstructive pulmonary disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Predictors of atopic disease in children of women with asthma

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

Many patients with psoriasis fail to respond to biologic drugs either initially or lose response over time, the latter having predominantly been linked to low circulating drug levels. We examined how serum drug levels varied over three treatment cycles of stable maintenance therapy with either adalimumab or infliximab among a total of 28 patients with psoriasis (22 men, mean age 48.6 years, mean treatment time 6.2 years) and whether there was an association with various patient-specific factors. The range for all concentrations was 1.1 to 24.3 μg/mL for adalimumab and 0.0 to 180.6 μg/mL for infliximab. There was a consistent inverse association between body mass index (BMI) and trough and maximum serum concentrations of adalimumab (P < .05 for all comparisons) and a positive, less consistent, association between age and maximum serum concentration of infliximab (P < .05 for both comparisons). Patient-specific factors, such as BMI and age, can help predict fluctuations in serum concentrations of biologics used for psoriasis.

Original languageEnglish
Article numbere13497
JournalDermatologic Therapy
Volume33
Issue number4
Pages (from-to)e13497
ISSN1396-0296
DOIs
Publication statusPublished - Jul 2020

    Research areas

  • adalimumab, drug levels, infliximab, psoriasis

ID: 61719898